Lou Portero

Urban Health Today

Distinctive epigenetic pathways were discovered in African American and European American patients with multiple myeloma (MM), according to a Northwestern Medicine study<a href="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01327-y"> published</a> in the Journal of Hematology and Oncology.The study carried out by Wei Zhang, Ph.D., and colleagues at Northwestern Medicine examined the contribution of 5-hydroxymethylcytosines (5hmC), a known epigenetic biomarker of cancers, to racial disparities in MM.The researchers used 5hmC-Seal and next-generation sequencing to profile genome-wide 5hmC in circulating cell-free DNA (cfDNA) from 342 newly diagnosed patients with MMs. Two hundred and twenty-seven of these patients were European Americans, while one hundred and seventeen were African Americans. They also compared differential 5hmC modifications between MM and its precursors.Although the diagnosis of MM is rare, previous studies have found that African Americans are two to three times more likely than European Americans to be diagnosed.While risk variables such as socioeconomic status and obesity may contribute to the varied diagnosis rates in this patient population, they do not entirely explain the elevated risk in African Americans, according to Zhang.The researchers identified about five hundred genes with different 5hmC levels; of these top five hundred genes, about ninety-five percent were distinct between European Americans and African Americans. Specifically, they discovered that African American patients had more amino acid metabolism pathways, whereas European American patients had more cancer-related signaling pathways.According to the researchers, these findings helped them better understand the epigenetic contribution to racial disparities in MM and suggest epigenetic pathways that could be exploited as novel preventive strategies in high-risk populations.&ldquo;If we observe that population-specific 5hmC is related to differential patient survival, then we could actually utilize 5hmC as a novel biomarker that can help us monitor treatment response and detect patients with minimal residual disease in a population-specific way,&rdquo; said Zhang.&nbsp;Journal source:<a href="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01327-y"> BMC</a>Source: <a href="https://news.feinberg.northwestern.edu/2022/09/06/investigating-racial-differences-in-multiple-myeloma/">Northwestern.edu</a>

Rebecca Araujo

AI-Driven Insulin Support: Are These Tools Ready for Diabetes Care?

Diabetes

Heart Rate Complexity May Predict Cognitive Decline in Older Adults

Alzheimer's & Dementia

Female Cancer Survivors Face Higher Rates of Fatigue and Depression, Study Finds

Women's Neurology

Latest News

Epigenetic Biomarker Explains Racial Disparities in Patients With MM

Multiple Myeloma

Distinctive epigenetic pathways were discovered in African American and European American patients with multiple myeloma ...

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe